August 8th, 2018: Understanding and Remembrance Day for Severe ME
Have you heard of our Severe Myalgic Encephalomyelitis Day of Understanding and Remembrance? Please join Jody Smith in observing this day and honoring the 25% of those with ME/CFS who are most severely ill.
Discuss the article on the Forums.

Nexvax2: Treatment intended to restore tolerance to gluten

Discussion in 'Other Health News and Research' started by Waverunner, Jan 15, 2014.

  1. Waverunner

    Waverunner Senior Member

    Nexvax2 is currently in Phase 1. Hopefully the results are encouraging.

    Nexvax2® is one of an emerging class of therapeutic vaccines based on the same principles as “traditional”
    desensitization therapy for allergic conditions using whole proteins (ref. 4, 5). Peptide-based therapeutic vaccines have been successful in preventing and treating immune diseases in the laboratory (ref. 4). Major international programs are underway to discover and develop peptide-based therapeutic vaccines for multiple sclerosis, Type-1 diabetes, rheumatoid arthritis, and various allergic diseases including cat-sensitive asthma (ref. 4).

    However, discovery of relevant peptides causing human immune diseases has hindered pharmaceutical development of peptide-based therapeutic vaccines.

    Nexvax2® evolved from studies in patients with celiac disease who consumed gluten to deliberately reactivate the gluten immune response in a controlled manner. (ref. 9, 10) ImmusanT’s scientists identified gluten-derived peptides recognized by disease-causing immune cells
    (T cells) in volunteers with celiac disease after they ate gluten. It was discovered that celiac disease is uniquely suited for a peptide-based therapeutic vaccine because patients with the most common genetic version of the condition, who possess HLA DQ2, consistently have disease-causing T cells recognizing three short gluten peptides. (ref. 14)

    Nexvax2® has been designed for celiac disease associated HLA DQ2, present in 90% of individuals with celiac disease (ref. 6–8). Nexvax2® encompasses three peptides that account for a substantial proportion of the T-cell reaction to gluten in patients with HLA DQ2-associated celiac disease. ImmusanT’s scientists converted these peptides into a pharmaceutical agent, Nexvax2®. In laboratory studies, Nexvax2® is capable of inducing immune tolerance to gluten. ImmusanT is in clinical trials testing whether Nexvax2® induces immune tolerance to gluten and protects the intestine from the damaging effects of gluten.

See more popular forum discussions.

Share This Page